Marshall Wace’s Neumora Therapeutics NMRA Stock Holding History

Marshall Wace’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.33M	Buy	1,195,310 +611,552	+105%	+$1.58M	﹤0.01%	1699
2025 Q4	$1.04M	Buy	+583,758	New	+$1.28M	﹤0.01%	1901
2025 Q3	–	Sell	-250,490	Closed	-$183K	–	3231
2025 Q2	$183K	Buy	+250,490	New	+$190K	﹤0.01%	2472
2024 Q3	–	Sell	-134,545	Closed	-$1.32M	–	2817
2024 Q2	$1.32M	Buy	+134,545	New	+$1.39M	﹤0.01%	1556
2023 Q4	–	Sell	-256,412	Closed	-$3.62M	–	2470
2023 Q3	$3.62M	Buy	+256,412	New	+$3.2M	0.01%	992

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Marshall Wace's NMRA Position: Q1 2026 in Review

Marshall Wace increased its Neumora Therapeutics (NMRA) stake by 105% in Q1 2026, buying an estimated $1.58M and bringing the position to 1,195,310 shares worth $2.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1699.

Marshall Wace first reported a position in NMRA in Q3 2023 and has held it in 5 quarters since. The position peaked at $3.62M in Q3 2023. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

Marshall Wace held 1,195,310 shares of Neumora Therapeutics worth $2.33M as of Q1 2026.
Marshall Wace bought 611,552 Neumora Therapeutics shares in Q1 2026, an estimated $1.58M.
Neumora Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1699 holding.
Marshall Wace first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 5 quarters since.
Marshall Wace's Neumora Therapeutics position peaked at $3.62M in Q3 2023.
114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.